Breaks Categories: News

ThursdayMar 21, 2024 1:38 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has been granted an additional 180 days to comply with NASDAQ’s minimum bid price requirement for the continued listing on the NASDAQ Capital Market. InMed received a letter from the exchange notifying it of the extended deadline, which will now be Sept. 16, 2024. According to the announcement, the compliance issues have no immediate effect on the listing or trading of the InMed Pharmaceuticals’ ordinary shares, which will continue to trade on the NASDAQ Capital Market. “NASDAQ's determination is based on…

Continue Reading

ThursdayMar 14, 2024 3:06 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan, CPA, will serve in the position, which also entails being a member of Lexaria’s executive leadership team. Cabatuan brings more than 15 years of corporate finance and operations experience in the life sciences industry. Most recently, he served as senior vice president of finance and operations at Rain Oncology Inc., a late-stage precision oncology biotech company. In that position, he was pivotal in building and leading the company’s financial organization, resulting in significant growth…

Continue Reading

ThursdayMar 07, 2024 2:03 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO for Second DehydraTECH-Powered GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to perform the company’s second DehydraTECH-powered glucagon-like peptide 1 (“GLP-1”) human pilot study #2. According to the announcement, the study will be a randomized, crossover, placebo-controlled investigation that will compare three formulations, each at a 7 mg semaglutide dose: a positive control Rybelsus(R) swallowed tablet; DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. “DehydraTECH has previously shown an ability to improve delivery of certain drugs destined for the bloodstream, through the…

Continue Reading

TuesdayMar 05, 2024 3:26 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details for an eight-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol, alone and in combination. The contract for the study was awarded to a third-party, Health Canada-licensed research laboratory. Manufacturing of the compositions for the first eight of the 12 study arms has been completed, and those arms will commence as soon as possible at the testing laboratory, expected to begin within 45 days. Each arm of the study will be dosed for…

Continue Reading

FridayMar 01, 2024 12:15 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed the effectiveness of the company’s investigational new drug (“IND”) application thereby clearing Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD. According to the announcement, the company is pleased to have complied with the FDA’s rules and procedures for clearance to perform this important registrational trial. The company will further announce when it is ready to begin the study, subject to certain conditions, including raising sufficient funding. “This is a significant…

Continue Reading

TuesdayFeb 20, 2024 1:50 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has closed on a registered direct offering. The offering included the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) offered at $2.31 per share. The company also noted that, in a concurrent private placement, it issued unregistered warrants to purchase up to 1,558,443 shares of common stock. The shares were offered at an exercise price of $2.185 per share and were immediately exercisable upon issuance with an expiration date five years following the date of issuance. H.C. Wainwright & Co. acted…

Continue Reading

FridayFeb 09, 2024 1:31 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered more than two decades of experience in financial leadership roles, primarily in the biotech industry. Most recently, she was vice president of Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS), where she was a key player in the company’s initial public offering process; she…

Continue Reading

TuesdayJan 30, 2024 12:55 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”). The application covers HYPER-H23-1, the company’s upcoming planned U.S. phase 1b hypertension clinical trial of DehydraTECH-CBD. According to the announcement, the company had a successful pre-IND meeting with FDA officials. Following the guidance provided in that meeting regarding the development and filing of the IND, the company submitted the application on Jan. 29, 2024. The company will now wait 30 calendar days before initiating any clinical trials, in compliance with FDA guidelines.…

Continue Reading

FridayJan 19, 2024 2:04 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s chat is scheduled to begin at 1 p.m. ET on Jan. 25, 2024. According to the announcement, topics discussed during the event will include an overview of InMed’s pharmaceutical pipeline in Alzheimer’s and ocular as well as a discussion about cannabinoids and their possible role in the treatment of Alzheimer’s. In addition, the chat will include a look at upcoming 2024…

Continue Reading

TuesdayJan 16, 2024 3:16 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today unveiled a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global pharmaceutical companies. In a recent human pilot study with seven volunteers, Lexaria demonstrated superior pharmacokinetic (“PK”) oral delivery performance of the DehydraTECH-enhanced glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). The positive results were sufficient to encourage a much more thorough and expanded investigation. The objective of the new planned studies, as detailed in the announcement, is…

Continue Reading